Lauren E. Williamson

Lauren E. Williamson

Auto-generated profile, based on publicly available information

Lauren E. Williamson

The Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MVMatthew R Vogt
Matthew R Vogt
JFJianing Fu
Jianing Fu
NKNurgun Kose
Nurgun Kose
LWLauren E Williamson
Lauren E Williamson
RBRobin Bombardi
Robin Bombardi
JCJames E Crowe
James E Crowe
A human monoclonal antibody shows potential to prevent or treat acute flaccid myelitis associated with enterovirus D68 infection.

17 March 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
NKNatasha M. Kafai
Natasha M. Kafai
LWLauren E. Williamson
Lauren E. Williamson
EBElad Binshtein
Elad Binshtein
SSSoila Sukupolvi-Petty
Soila Sukupolvi-Petty
CGChristina L. Gardner
Christina L. Gardner
MDMichael Diamond
Michael Diamond
Venezuelan equine encephalitis virus (VEEV) remains a risk for epidemic emergence or use as an aerosolized bioweapon. To develop possible countermeasures, we isolated VEEV-specific neutralizing monoclonal antibodies (mAbs) from mice and a human immunized with attenuated VEEV strains. Functional assays and epitope mapping established that potently inhibitory anti-VEEV mAbs bind distinct antigenic sites in the A or B domains of the E2 glycoprotein and block multiple steps in the viral replication cycle including attachment, fusion, and egress. A 3.2-Å cryo-electron microscopy reconstruction of VEEV virus-like particles bound by a human Fab suggests that antibody engagement of the B domain may result in cross-linking of neighboring spikes to prevent conformational requirements for viral fusion. Prophylaxis or postexposure therapy with these mAbs protected mice against lethal aerosol challenge with VEEV. Our study defines functional and structural mechanisms of mAb protection and suggests that multiple antigenic determinants on VEEV can be targeted for vaccine or antibody-based therapeutic development.

17 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
PIPhilipp A. Ilinykh
Philipp A. Ilinykh
Kai HuangKai Huang
Kai Huang
BGBronwyn M. Gunn
Bronwyn M. Gunn
NKNATALIA KUZMINA
NATALIA KUZMINA
KKKritika Kedarinath
Kritika Kedarinath
Alexander BukreyevAlexander Bukreyev
Alexander Bukreyev
Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute the protection conferred by antibodies of various epitope specificities. At the same time, the role of the complement system remains unclear. Here, we compare complement activation by two groups of representative monoclonal antibodies (mAbs) interacting with the glycan cap (GC) or the membrane-proximal external region (MPER) of GP. Binding of GC-specific mAbs to GP induces complement-dependent cytotoxicity (CDC) in the GP-expressing cell line via C3 deposition on GP in contrast to MPER-specific mAbs. In the mouse model of EBOV infection, depletion of the complement system leads to an impairment of protection exerted by one of the GC-specific, but not MPER-specific mAbs. Our data suggest that activation of the complement system represents an important mechanism of antiviral protection by GC antibodies.

12 March 2026 in Nature Microbiology
Verified
Journal Article
Open access
SZSeth J. Zost
Seth J. Zost
NSNaveenchandra Suryadevara
Naveenchandra Suryadevara
LWLauren E. Williamson
Lauren E. Williamson
SSSuzanne M. Scheaffer
Suzanne M. Scheaffer
EBElad Binshtein
Elad Binshtein
JCJames E. Crowe
James E. Crowe
The emergence of SARS-CoV-2 Omicron variants has led to viral escape from many clinically approved monoclonal antibodies (mAbs) due to rapid evolution of the receptor-binding domain (RBD). Co-circulation of SARS-CoV-2 variants with unique sets of antigenic substitutions has further complicated therapeutic mAb discovery. New approaches are needed to rapidly discover and characterize mAbs with preferred specificity and functional characteristics. Here we describe and perform epitope-focused mAb discovery using glycan-masked antigens. We isolated and expressed a panel of 303 mAbs, some of which potently neutralize divergent Omicron subvariants by targeting the class 3 antigenic site on SARS-CoV-2 RBD. Epitope mapping of these antibodies revealed a spectrum of cross-reactivity and differential recognition of the class 3 site, validating the utility of this enrichment approach for targeted mAb discovery. Together, this work rationally designs glycan-masked engineered RBDs and uses them to isolate mAbs that potently neutralize antigenically divergent SARS-CoV-2 variants.

19 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAbhishek Bandyopadhyay
Abhishek Bandyopadhyay
LWLauren E. Williamson
Lauren E. Williamson
DSDevika Sirohi
Devika Sirohi
KBKevin Bailey
Kevin Bailey
TGTheron Gilliland
Theron Gilliland
Richard KuhnRichard Kuhn
Richard Kuhn
Eastern equine encephalitis virus (EEEV) is a mosquito-transmitted alphavirus that can cause severe encephalitis in humans and horses with a high case fatality rate. There are no licensed EEEV vaccines or therapeutics for human use, warranting the need to better understand the human immune response against EEEV. Here we present a cryo-EM reconstruction of the chimeric virus, Sindbis (SINV)/EEEV, in complex with a potently neutralizing and efficacious intact human IgG1 antibody in a mouse model of infection and disease. This antibody requires bivalency to recognize a quaternary epitope on the E2 glycoprotein and cross-links two virus spikes across the icosahedral two-fold axis through a unique binding mode. Kinetic analysis of the binding interaction provides insights into this distinguishing feature. Mechanistically, the antibody inhibits viral entry into cells through blockade of receptor binding and early fusion events but does not block egress, thereby, exclusively targeting an epitope found on intact virions. The discovery of the quaternary epitope and unique binding mode recognized by this antibody together advance our understanding of the complexity of antibody-antigen interactions and can aid in vaccine design to elicit recognition of distinct epitopes of clinically relevant alphaviruses.

31 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
PIPhilipp A. Ilinykh
Philipp A. Ilinykh
Kai HuangKai Huang
Kai Huang
BGBronwyn M. Gunn
Bronwyn M. Gunn
NKNATALIA KUZMINA
NATALIA KUZMINA
KKKritika Kedarinath
Kritika Kedarinath
Alexander BukreyevAlexander Bukreyev
Alexander Bukreyev
Complement" but should have been "Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system".